痛风过早死亡差距未缩小:一项基于普通人群的研究
该研究基于英国普通人群电子病历数据库,纳入1999至2014年新发痛风患者及对照,按诊断年份分为早期(1999-2006)和晚期(2007-2014)队列,比较两队列的死亡率和风险比。结果显示两队列痛风患者均存在相似的超额死亡,多变量HR分别为1.10(95%CI 1.06-1.15)和1.09(95%CI 1.05-1.13),交互作用p>0.72;敏感性分析结果相似。结论指出痛风过早死亡水平在过去16年未改善,不同于类风湿关节炎。
要点
- 痛风患者两队列均显示超额死亡,多变量HR分别为1.10和1.09。
- 早晚期队列死亡率HR分别为1.25和1.24,交互作用p>0.72。
- 敏感性分析结果相似,交互作用p>0.88。
核心结论
- 痛风患者过早死亡水平在过去16年未改善,不同于同期类风湿关节炎的改善趋势。
- 这一未缩小的过早死亡差距提示需要改进痛风及其合并症的管理。
研究设计与样本
- 基于英国普通人群代表性电子病历数据库的队列研究,识别1999至2014年新发痛风病例和对照。
- 痛风队列按诊断年份分为早期(1999-2006)和晚期(2007-2014)队列,比较死亡率和HR,并调整潜在混杂因素。
- 敏感性分析纳入至少接受一次降尿酸治疗处方的痛风患者(该定义有效性为90%)。
主要发现
- 早期队列痛风患者死亡率为29.1/1000人年,对照为23.5/1000人年;晚期队列分别为23.0/1000人年和18.8/1000人年。
- 早期和晚期队列的死亡率HR分别为1.25(95%CI 1.21-1.30)和1.24(95%CI 1.20-1.29)。
- 多变量HR分别为1.10(95%CI 1.06-1.15)和1.09(95%CI 1.05-1.13),交互作用p值均>0.72。
- 敏感性分析显示相似结果,交互作用p值均>0.88。
临床怎么用
- 临床应重视痛风患者的过早死亡风险,并积极管理其合并症。
- 需改进痛风整体管理以缩小未改善的死亡差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gout, the most common inflammatory arthritis, is associated with premature mortality. Whether this mortality gap has improved over time, as observed in rheumatoid arthritis (RA), is unknown. METHODS: Using an electronic medical record database representative of the UK general population, we identified incident gout cases and controls between 1999 and 2014. The gout cohort was divided based on year of diagnosis into early (1999-2006) and late (2007-2014) cohorts. We compared the mortality rates and HRs, adjusting for potential confounders between the cohorts. We conducted sensitivity analyses among patients with gout who received at least one prescription for urate-lowering therapy, which has been found to have a validity of 90%. RESULTS: In both cohorts, patients with gout showed similar levels of excess mortality compared with their corresponding comparison cohort (ie, 29.1 vs 23.5 deaths/1000 person-years and 23.0 vs 18.8 deaths/1000 person-years in the early and late cohorts, respectively). The corresponding mortality HRs were 1.25 (95% CI 1.21 to 1.30) and 1.24 (95% CI 1.20 to 1.29), and the multivariable HRs were 1.10 (95% CI 1.06 to 1.15) and 1.09 (95% CI 1.05 to 1.13), respectively (both p values for interaction >0.72). Our sensitivity analyses showed similar findings (both p values for interaction >0.88). CONCLUSIONS: This general population-based cohort study indicates that the level of premature mortality among patients with gout remains unimproved over the past 16 years, unlike RA during the same period. This unclosing premature mortality gap calls for improved management of gout and its comorbidities.
引用
- Fisher MC, Rai SK, Lu N, et al. The unclosing premature mortality gap in gout: a general population-based study. Ann Rheum Dis. 2017. PMID: 28122760. doi:10.1136/annrheumdis-2016-210588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。